Assertio Holdings (ASRT) Stock

LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee.

LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of Rolvedon ® (eflapegrastim-xnst) injection when dosed the same day of chemotherapy for patients with early stage breast cancer (ESBC).

CTV, GRAB, ASRT, POWL and LUV have been added to the Zacks Rank #1 (Strong Buy) List on December 10, 2024.

MKTAY, ASRT, CHH, DRS and BRKL have been added to the Zacks Rank #1 (Strong Buy) List on November 29, 2024.

Call Start: 16:30 January 1, 0000 5:03 PM ET Assertio Holdings, Inc. (NASDAQ:ASRT ) Q3 2024 Earnings Conference Call November 11, 2024 04:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Brendan O'Grady - CEO Ajay Patel - SVP & CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Naz Rahman - Maxim Group Scott Henry - Alliance Global Partners Raghuram Selvaraju - H.C. Wainwright Operator Thank you for standing by.

Assertio (ASRT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.01 per share a year ago.

Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million  Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the third quarter ended September 30, 2024.

Claims about Rolvedon and Assertio's Accounting Practices are False and Baseless Short-seller's Press Release is Another Improper Attempt to Enrich Himself at Assertio's Expense Company Considering Taking Legal and Regulatory Action LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today issued the following letter from Chief Executive Officer Brendan O'Grady in response to public comments made November 8, 2024 by a short-seller: To the members of the investment community, As many of you have been aware, Mr.

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that has now inverted its long equity position into that of a short interest in the publicly traded securities of Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today released an open letter to Assertio stockholders. “Today, BHG has sadly been forced to issue a letter to Assertio stockholders, in light of the bo.